IS2181B - Pýrasóló[4,3-d]pýrimidín afleiður - Google Patents
Pýrasóló[4,3-d]pýrimidín afleiðurInfo
- Publication number
- IS2181B IS2181B IS6320A IS6320A IS2181B IS 2181 B IS2181 B IS 2181B IS 6320 A IS6320 A IS 6320A IS 6320 A IS6320 A IS 6320A IS 2181 B IS2181 B IS 2181B
- Authority
- IS
- Iceland
- Prior art keywords
- pyrazolo
- pyrimidine derivatives
- pyrimidine
- derivatives
- Prior art date
Links
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9924063.2A GB9924063D0 (en) | 1999-10-11 | 1999-10-11 | Pharmaceutically active compounds |
GB0018656A GB0018656D0 (en) | 2000-07-28 | 2000-07-28 | Pharmaceutically active compounds |
PCT/IB2000/001457 WO2001027113A2 (en) | 1999-10-11 | 2000-10-11 | PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES |
Publications (2)
Publication Number | Publication Date |
---|---|
IS6320A IS6320A (is) | 2002-03-21 |
IS2181B true IS2181B (is) | 2006-12-15 |
Family
ID=26244757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS6320A IS2181B (is) | 1999-10-11 | 2002-03-21 | Pýrasóló[4,3-d]pýrimidín afleiður |
Country Status (48)
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235625B2 (en) | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
GB0000561D0 (en) * | 2000-01-11 | 2000-03-01 | Pfizer Ltd | Treatment of diabetic ulcers |
US6774128B2 (en) * | 2000-04-19 | 2004-08-10 | Johns Hopkins University | Methods for prevention and treatment of gastrointestinal disorders |
US6271228B1 (en) * | 2000-04-28 | 2001-08-07 | Pfizer Inc. | Blood pressure stabilization during hemodialysis |
EP1176142A1 (en) * | 2000-07-28 | 2002-01-30 | Pfizer Inc. | Process for the preparation of pyrazoles |
US6420557B1 (en) | 2000-07-28 | 2002-07-16 | Pfizer Inc. | Crystalline therapeutic agent |
SK572003A3 (en) * | 2000-07-28 | 2004-05-04 | Pfizer | Crystalline therapeutic agent |
US6407259B1 (en) | 2000-07-28 | 2002-06-18 | Pfizer Inc. | Process for the preparation of pyrazoles |
GB0025782D0 (en) * | 2000-10-20 | 2000-12-06 | Pfizer Ltd | Use of inhibitors |
US6548508B2 (en) | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
FR2820319B3 (fr) * | 2001-02-08 | 2003-12-05 | Ellipse Pharmaceuticals | Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu |
DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
AU2003223071A1 (en) * | 2002-05-23 | 2003-12-12 | Pfizer Inc. | Pharmaceutical combination of PDE5 inhibitors with ACE inhibitors |
GB0214784D0 (en) * | 2002-06-26 | 2002-08-07 | Pfizer Ltd | Novel combination |
DE10229778A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Neue Verwendung von Imidazotriazinonen |
GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
EP2196201A3 (en) | 2002-12-13 | 2010-12-08 | Warner-Lambert Company LLC | Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms |
PL378296A1 (pl) | 2003-02-27 | 2006-03-20 | Palau Pharma S.A. | Pochodne pirazolopirydyny |
JP4015176B2 (ja) | 2003-04-29 | 2007-11-28 | ファイザー・インク | 高血圧症の治療に有用な5,7−ジアミノピラゾロ4,3−ジピリミジン類 |
JP2006527257A (ja) * | 2003-06-10 | 2006-11-30 | ファイザー・インク | 月経困難症の治療用のpde阻害剤及びバソプレッシン受容体アンタゴニストを含んでなる療法組合せ |
JP2006219373A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
US7291640B2 (en) | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
DE10360835A1 (de) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
WO2005097799A1 (en) | 2004-04-07 | 2005-10-20 | Pfizer Limited | Pyrazolo`4,3-d! pyrimidines |
WO2006100557A1 (en) | 2005-03-21 | 2006-09-28 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
MX2007013215A (es) | 2005-05-12 | 2007-12-12 | Pfizer | Formas cristalinas anhidras de la n-[1-(2-etoxietil)-5-(n-etil-n- metilamino)-7-(4-metilpiridin-2-il-amino)-1h-pirazolo[4,3-d] pirimidina -3-carbonil] metanosulfonamida. |
CN101248050B (zh) | 2005-06-06 | 2013-07-17 | 武田药品工业株式会社 | 有机化合物 |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
KR20080076961A (ko) * | 2005-12-20 | 2008-08-20 | 화이자 프로덕츠 인크. | Pde5 억제제 및 무스카린성 길항제를 포함하는luts의 치료를 위한 약제학적 조합물 |
CA2633570A1 (en) * | 2005-12-21 | 2007-06-28 | Pfizer Products Inc. | Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor |
UY30111A1 (es) * | 2006-02-03 | 2007-04-30 | Recordati Ireland Ltd | Sales de adicion de acido de n-(3-(4-(2-metoxifenil)-1-piperazinil)-propil)-7-oxo-5-trifluormetil-7h-tieno (3,2-b) piran-3-carboxamida |
US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
US20070244143A1 (en) * | 2006-03-08 | 2007-10-18 | Braincells, Inc | Modulation of neurogenesis by nootropic agents |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
AU2007249435A1 (en) * | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
MX2008015489A (es) | 2006-06-06 | 2009-01-13 | Intra Cellular Therapies Inc | Compuestos organicos. |
US20080051413A1 (en) * | 2006-08-25 | 2008-02-28 | Kaohsiung Medical University | Nitrophenylpiperazine derivative of xanthine which relaxes tracheal airway and increases respiratory performance |
AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
CA2663347A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | Ppar mediated modulation of neurogenesis |
US20080081816A1 (en) * | 2006-10-03 | 2008-04-03 | Kaohsiung Medical University | Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3 |
US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
CA2707218A1 (en) | 2007-12-06 | 2009-06-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
CA2740398A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
PE20110995A1 (es) | 2008-12-06 | 2012-02-06 | Intra Cellular Therapies Inc | DERIVADOS DE PIRROLO[3,4-e]PIRIMIDINA COMO INHIBIDORES DE PDE1 |
MX2011005934A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
EP2358723B1 (en) | 2008-12-06 | 2015-05-13 | Intra-Cellular Therapies, Inc. | 4,5,7,8-tetrahydro-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors |
PE20110922A1 (es) | 2008-12-06 | 2012-01-22 | Intra Cellular Therapies Inc | DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1) |
ES2580759T3 (es) | 2008-12-06 | 2016-08-26 | Intra-Cellular Therapies, Inc. | Compuestos orgánicos |
EP2379076B1 (en) | 2008-12-23 | 2014-11-12 | The Trustees of Columbia University in the City of New York | Phosphodiesterase inhibitors and uses thereof |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
WO2010132127A1 (en) | 2009-05-13 | 2010-11-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
US9371327B2 (en) | 2010-05-31 | 2016-06-21 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
EP2575817A4 (en) | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
EP2576551A4 (en) | 2010-05-31 | 2014-04-16 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
WO2012171016A1 (en) | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2013067309A1 (en) | 2011-11-04 | 2013-05-10 | Xion Pharmaceutical Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
WO2013109738A1 (en) | 2012-01-17 | 2013-07-25 | The Trustees Of Columbia University In The City Of New York | Novel phosphodiesterase inhibitors and uses thereof |
AR091507A1 (es) | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
JP6549040B2 (ja) | 2013-02-17 | 2019-07-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規使用 |
CA2906640C (en) | 2013-03-15 | 2021-07-20 | Intra-Cellular Therapies, Inc. | Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors |
EP2968338B1 (en) | 2013-03-15 | 2019-01-09 | Intra-Cellular Therapies, Inc. | Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries |
BR112015032132B1 (pt) * | 2013-06-21 | 2022-03-15 | Intra-Cellular Therapies, Inc | Composto de base livre, composto na forma cristalina, processo para preparar uma forma cristalina de base livre e processo para preparar uma forma cristalina de sal de monofosfato do composto a |
ES2776353T3 (es) | 2013-07-17 | 2020-07-30 | Univ Columbia | Inhibidores de la fosfodiesterasa novedosos y usos de los mismos |
AR102315A1 (es) * | 2014-04-02 | 2017-02-22 | Bayer Cropscience Ag | Derivados de pirazolil-nicotin(tio)amida sustituidos y su uso como fungicidas |
WO2015196186A1 (en) | 2014-06-20 | 2015-12-23 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
ES2745819T3 (es) | 2014-08-07 | 2020-03-03 | Intra Cellular Therapies Inc | Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1 |
US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
IL292225B2 (en) | 2014-09-17 | 2024-12-01 | Intra Cellular Therapies Inc | Derivatives of 5,7,7-trimethyl-[2H]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one and pharmaceutical compositions comprising them. |
WO2017172795A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
MX389700B (es) | 2016-09-09 | 2025-03-20 | Incyte Corp | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. |
US11291666B2 (en) | 2016-09-12 | 2022-04-05 | Intra-Cellular Therapies, Inc. | Uses |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
JP7401442B2 (ja) | 2018-01-31 | 2023-12-19 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
CN112292380B (zh) | 2018-02-20 | 2024-04-05 | 因赛特公司 | 作为用于治疗癌症的hpk1抑制剂的n-(苯基)-2-(苯基)嘧啶-4-甲酰胺衍生物及相关化合物 |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
US11111247B2 (en) | 2018-09-25 | 2021-09-07 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
EP4010338A1 (en) | 2019-08-06 | 2022-06-15 | Incyte Corporation | Solid forms of an hpk1 inhibitor |
US12410175B2 (en) | 2019-09-03 | 2025-09-09 | Intra-Cellular Therapies, Inc. | Compounds |
US11590209B2 (en) | 2020-01-21 | 2023-02-28 | Palatin Technologies, Inc. | Use of bremelanotide in patients with controlled hypertension |
CN113493459B (zh) * | 2020-04-07 | 2022-12-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | Pde5抑制剂化合物及其制备方法和应用 |
US12435093B2 (en) | 2020-05-06 | 2025-10-07 | Intra-Cellular Therapies, Inc. | Free base crystals |
US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2089971A (en) | 1937-08-17 | Condensation products of | ||
DE425921C (de) * | 1923-08-11 | 1926-02-27 | Ernst Otto Baum | Pressluftzugmaschine fuer Bergwerke |
US4871843A (en) | 1983-10-18 | 1989-10-03 | Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle | Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions |
FR2558263B1 (fr) * | 1984-01-12 | 1986-04-25 | Commissariat Energie Atomique | Accelerometre directif et son procede de fabrication par microlithographie |
US4663326A (en) | 1985-04-04 | 1987-05-05 | Warner-Lambert Company | Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs |
US4666908A (en) | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
US5075310A (en) | 1988-07-01 | 1991-12-24 | Smith Kline & French Laboratories, Ltd. | Pyrimidone derivatives as bronchodilators |
GB8817651D0 (en) | 1988-07-25 | 1988-09-01 | Smith Kline French Lab | Chemical compounds |
IL95975A (en) | 1989-10-24 | 1997-06-10 | Takeda Chemical Industries Ltd | N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9114760D0 (en) | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
GB9202238D0 (en) | 1992-02-03 | 1992-03-18 | Wellcome Found | Compounds |
US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
US5734053A (en) | 1992-06-26 | 1998-03-31 | Pfizer Inc | Purinone antianginal agents |
GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
GB9301192D0 (en) * | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
GB9315017D0 (en) | 1993-07-20 | 1993-09-01 | Glaxo Lab Sa | Chemical compounds |
US5728705A (en) | 1993-10-04 | 1998-03-17 | The Trustees Of Columbia University In The City Of New York | Method of inducing vasorelaxation to treat pulmonary hypertension |
GB9423911D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
GB9423910D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
US5656629A (en) | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
WO1996028448A1 (en) | 1995-03-10 | 1996-09-19 | Sanofi Winthrop, Inc. | 6-ARYL PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF |
US5952006A (en) | 1995-09-29 | 1999-09-14 | L.A.M. Pharmaceuticals, Llc | Drug preparations for treating impotency |
DE19540642A1 (de) | 1995-11-01 | 1997-05-07 | Stief Christian Georg Priv Doz | Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen |
GB9612514D0 (en) | 1996-06-14 | 1996-08-14 | Pfizer Ltd | Novel process |
CZ299633B6 (cs) * | 1997-04-25 | 2008-09-24 | Pfizer Inc. | Pyrazolopyrimidinony, meziprodukty pro jejich výrobu a farmaceutické a veterinární kompozice na jejich bázi |
WO1998052569A1 (en) | 1997-05-19 | 1998-11-26 | Zonagen, Inc. | Combination therapy for modulating the human sexual response |
EP0992240A4 (en) | 1997-05-29 | 2003-04-16 | Mochida Pharm Co Ltd | THERAPEUTIC AGENT FOR TREATING ANERECTION |
JP2002508315A (ja) | 1997-12-16 | 2002-03-19 | ファイザー・プロダクツ・インク | 性的不能の治療に有効な組合せ |
SI1371647T1 (en) * | 1998-04-20 | 2005-10-31 | Pfizer Inc. | Pyridine-3-carboxylic acid derivatives and their use as intermediates |
AU4068599A (en) | 1998-05-20 | 1999-12-06 | Schering Corporation | Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction |
US6087368A (en) | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
WO2000020033A1 (fr) | 1998-10-05 | 2000-04-13 | Eisai Co., Ltd. | Comprimes se delitant immediatement dans la cavite buccale |
JP2000119198A (ja) | 1998-10-16 | 2000-04-25 | Eisai Co Ltd | 苦味等の隠蔽されたホスフォジエステラーゼ阻害剤含有経口製剤 |
CA2251255A1 (en) | 1998-10-20 | 2000-04-20 | Mcgill University | The use of dopaminergic agents in the management of sexual dysfunction |
IL132406A0 (en) | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
GB9823101D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
CA2347950C (en) | 1998-10-23 | 2005-05-03 | Pfizer Inc. | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
GB9828340D0 (en) | 1998-12-22 | 1999-02-17 | Novartis Ag | Organic compounds |
JP3199115B2 (ja) * | 1998-12-24 | 2001-08-13 | モトローラ株式会社 | デジタル・アナログ変換回路 |
DE19903087A1 (de) | 1999-01-27 | 2000-08-10 | Forssmann Wolf Georg | Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern |
CA2362918A1 (en) | 1999-03-08 | 2000-09-14 | Elizabeth Stoner | Methods and compositions for treating erectile dysfunction |
IL137429A0 (en) | 1999-07-28 | 2001-07-24 | Pfizer Prod Inc | Methods and compsitions for treating diseases and conditions of the eye |
AU5957600A (en) | 1999-07-30 | 2001-02-19 | Lakefield Minerals Ltd. | Pharmaceutical compositions for topical application to treat erectile dysfunction |
WO2001010406A2 (en) | 1999-08-10 | 2001-02-15 | Board Of Regents, The University Of Texas System | Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow |
US6436944B1 (en) | 1999-09-30 | 2002-08-20 | Pfizer Inc. | Combination effective for the treatment of impotence |
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
YU59100A (sh) | 1999-10-11 | 2003-10-31 | Pfizer Inc. | Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera |
US6407259B1 (en) * | 2000-07-28 | 2002-06-18 | Pfizer Inc. | Process for the preparation of pyrazoles |
US6420557B1 (en) * | 2000-07-28 | 2002-07-16 | Pfizer Inc. | Crystalline therapeutic agent |
-
2000
- 2000-09-14 TW TW089118861A patent/TWI265925B/zh not_active IP Right Cessation
- 2000-10-06 US US09/685,080 patent/US6677335B1/en not_active Expired - Fee Related
- 2000-10-09 EG EG20001281A patent/EG24411A/xx active
- 2000-10-09 PH PH12000002783A patent/PH12000002783B1/en unknown
- 2000-10-09 MY MYPI20004712A patent/MY130319A/en unknown
- 2000-10-10 GT GT200000171A patent/GT200000171A/es unknown
- 2000-10-10 TN TNTNSN00199A patent/TNSN00199A1/fr unknown
- 2000-10-10 PA PA20008504501A patent/PA8504501A1/es unknown
- 2000-10-11 EA EA200200337A patent/EA004982B1/ru not_active IP Right Cessation
- 2000-10-11 CN CNB2005100625827A patent/CN100378100C/zh not_active Expired - Fee Related
- 2000-10-11 AP APAP/P/2002/002456A patent/AP1238A/en active
- 2000-10-11 SI SI200030593T patent/SI1220856T1/xx unknown
- 2000-10-11 NZ NZ518078A patent/NZ518078A/en unknown
- 2000-10-11 HR HR20020317A patent/HRP20020317B1/xx not_active IP Right Cessation
- 2000-10-11 CA CA002387357A patent/CA2387357C/en not_active Expired - Fee Related
- 2000-10-11 AU AU76784/00A patent/AU779065B2/en not_active Ceased
- 2000-10-11 PT PT00966347T patent/PT1220856E/pt unknown
- 2000-10-11 DE DE60016615T patent/DE60016615T2/de not_active Expired - Lifetime
- 2000-10-11 OA OA1200200104A patent/OA12061A/en unknown
- 2000-10-11 EP EP00966347A patent/EP1220856B1/en not_active Expired - Lifetime
- 2000-10-11 SV SV2000000195A patent/SV2002000195A/es unknown
- 2000-10-11 AT AT00966347T patent/ATE284404T1/de not_active IP Right Cessation
- 2000-10-11 RS YUP-314/02A patent/RS50476B/sr unknown
- 2000-10-11 GE GEAP20006408A patent/GEP20033142B/en unknown
- 2000-10-11 JP JP2001530331A patent/JP3834236B2/ja not_active Expired - Fee Related
- 2000-10-11 BR BR0014698-6A patent/BR0014698A/pt not_active Application Discontinuation
- 2000-10-11 IL IL14902600A patent/IL149026A0/xx unknown
- 2000-10-11 CO CO00077467A patent/CO5251477A1/es not_active Application Discontinuation
- 2000-10-11 DZ DZ003220A patent/DZ3220A1/fr active
- 2000-10-11 GE GEAP20005578A patent/GEP20033068B/en unknown
- 2000-10-11 WO PCT/IB2000/001457 patent/WO2001027113A2/en active Application Filing
- 2000-10-11 ES ES00966347T patent/ES2232502T3/es not_active Expired - Lifetime
- 2000-10-11 EE EEP200200195A patent/EE05181B1/xx not_active IP Right Cessation
- 2000-10-11 CN CNB008151954A patent/CN1204138C/zh not_active Expired - Fee Related
- 2000-10-11 PL PL00357536A patent/PL357536A1/xx not_active Application Discontinuation
- 2000-10-11 CN CNB2004100384099A patent/CN100383141C/zh not_active Expired - Fee Related
- 2000-10-11 DK DK00966347T patent/DK1220856T3/da active
- 2000-10-11 CZ CZ20021158A patent/CZ20021158A3/cs unknown
- 2000-10-11 SK SK460-2002A patent/SK4602002A3/sk unknown
- 2000-10-11 PE PE2000001090A patent/PE20010737A1/es not_active Application Discontinuation
- 2000-10-11 KR KR1020027004643A patent/KR100549152B1/ko not_active Expired - Fee Related
- 2000-10-11 TR TR2002/00989T patent/TR200200989T2/xx unknown
- 2000-10-11 HU HU0203450A patent/HUP0203450A3/hu unknown
-
2002
- 2002-03-21 CU CU20020060A patent/CU23198A3/es not_active IP Right Cessation
- 2002-03-21 IS IS6320A patent/IS2181B/is unknown
- 2002-03-28 IN IN385MU2002 patent/IN2002MU00385A/en unknown
- 2002-04-05 MA MA26586A patent/MA26825A1/fr unknown
- 2002-04-08 IL IL149026A patent/IL149026A/en not_active IP Right Cessation
- 2002-04-08 CR CR6617A patent/CR6617A/es not_active Application Discontinuation
- 2002-04-10 NO NO20021694A patent/NO322856B1/no not_active IP Right Cessation
- 2002-04-10 MX MXPA02003627 patent/MX228340B/es active IP Right Grant
- 2002-05-09 BG BG106678A patent/BG106678A/bg unknown
-
2004
- 2004-01-06 US US10/753,199 patent/US7176311B2/en not_active Expired - Fee Related
-
2005
- 2005-01-28 IN IN80MU2005 patent/IN2005MU00080A/en unknown
-
2006
- 2006-03-08 IN IN264MU2006 patent/IN2006MU00264A/en unknown
- 2006-08-11 US US11/463,931 patent/US20060293347A1/en not_active Abandoned
-
2007
- 2007-04-19 IN IN567MU2007 patent/IN2007MU00567A/en unknown
-
2008
- 2008-08-08 CR CR10191A patent/CR10191A/es not_active Application Discontinuation
-
2009
- 2009-05-20 US US12/469,311 patent/US20100035891A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1220856T3 (da) | Pyrazolo[4,3-d]pyrimidinderivater | |
MA26851A1 (fr) | Derives de pyrrolo [2,3-d] pyrimidine | |
DK1087971T3 (da) | Pyrrolo[2,3-d]pyrimidinforbindelser | |
DK1416935T3 (da) | 4-Amino-6-phenyl-pyrrolo[2,3-d]pyrimidinderivater | |
DE69915675D1 (de) | Triazolo[4,5-d]pyrimidin-derivate | |
ID26698A (id) | SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA | |
DE69804273D1 (de) | 5h-Thiazolo[3,2-a]pyrimidinderivate | |
DE50001191D1 (de) | Pyrazolo[4, 3-d]pyrimidine | |
DE60103909D1 (de) | 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate | |
NO995033D0 (no) | 6,7-disubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser | |
NO995035D0 (no) | 5,6,7-trisubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser | |
PT1326866E (pt) | 3,4-di-hidropirido[1,2-a]pirimidinas substituidas | |
ZA200202763B (en) | Pyrazolo [4,3-D] pyrimidine derivatives. | |
DK1326866T3 (da) | Substituerede 3,4-dihydro-pyrido[1,2-a]pyrimidiner |